The objective of this study was to investigate the prevalence of depression, anxiety, and insomnia among hospital staff working in a tertiary care private hospital in India during the early period of the COVID-19 pandemic.
In this commentary, the authors discuss coronaphobia and the advancements that have been made to understand, measure, and treat this reaction to stress related to COVID-19.
There is limited research on how a large-scale pandemic affects different aspects of OCD. Here, read about 2 cases in which there was significant deterioration in symptoms of OCD in the context of the COVID-19 pandemic.
Because of COVID-19, much behavioral health care is now delivered virtually. Is this as effective as in-person treatment? Read the article to learn more.
This study sought to identify patients vulnerable to worsening mental health during the early COVID-19 pandemic. Read this article to learn about the dramatic changes in psychiatric care experienced by these patients.
In this editorial, Larry Culpepper, MD, PCC Editor in Chief, discusses the 3 pandemics currently affecting patients with mental illness and thanks reviewers for their service in 2020.
This study assessed craving and withdrawal coping mechanisms used by patients with substance use disorders due to disruption in availability of substances and medications due to sudden lockdown in response to COVID-19.
Self-isolation measures, while important in curbing the spread and impact of COVID-19, are likely to increase rates of anxiety and depression. Here, a case is presented of COVID-19–related anxiety leading to late-onset psychotic and catatonic depression.
The psychiatric sequelae of the currently evolving COVID-19 pandemic are not yet clear. This report describes a case of panic disorder in a patient with COVID-19 infection.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT